Skeletal Effects of Primary Hyperparathyroidism: Bone Mineral Density and Fracture Risk

Journal of Clinical Densitometry

Volumn 16, Issue 1, 2013, Pages 28-32

  Lewiecki, E Michael ^a   Miller, Paul D ^b  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b Health Sciences Center and Colorado Center for Bone Research   (United States)

Author keywords

BMD; Cortical; Fracture; Hyperparathyroidism; Osteoporosis; Trabecular

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE[1-34];

ARTICLE; BONE DENSITY; BONE REMODELING; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FRACTURE; HIGH RISK POPULATION; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; OSTEOPOROSIS; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

EID: 84873209508     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.11.013     Document Type: Article

References (46)

1. Carney J.A. The glandulae parathyroideae of Ivar Sandstrom. Contributions from two continents. Am J Surg Pathol 1996, 20(9):1123-1144.
2. Triantafillidou K., Zouloumis L., Karakinaris G., et al. Brown tumors of the jaws associated with primary or secondary hyperparathyroidism. A clinical study and review of the literature. Am J Otolaryngol 2006, 27(4):281-286.
3. Meydan N., Barutca S., Guney E., et al. Brown tumors mimicking bone metastases. J Natl Med Assoc 2006, 98(6):950-953.
4. Genant H.K., Baron J.M., Straus F.H., et al. Osteosclerosis in primary hyperparathyroidism. Am J Med 1975, 59(1):104-113.
5. Silverberg S.J., Bilezikian J.P. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81(6):2036-2040.
6. Lowe H., McMahon D.J., Rubin M.R., et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007, 92(8):3001-3005.
7. Datta N.S., Abou-Samra A.B. PTH and PTHrP signaling in osteoblasts. Cell Signal 2009, 21(8):1245-1254.
8. Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999, 140(8):3552-3561.
9. Dempster D.W., Hughes-Begos C.E., Plavetic-Chee K., et al. Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 2005, 95(1):139-148.
10. Dobnig H., Turner R.T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138(11):4607-4612.
11. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40(6):1434-1446.
12. Kramer I., Keller H., Leupin O., Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab 2010, 21(4):237-244.
13. Christiansen P., Steiniche T., Brixen K., et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 1997, 21(1):93-99.
14. Parisien M., Silverberg S.J., Shane E., et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990, 70(4):930-938.
15. Barger-Lux M.J., Recker R.R. Bone microstructure in osteoporosis: transilial biopsy and histomorphometry. Top Magn Reson Imaging 2002, 13(5):297-305.
16. Dempster D.W., Parisien M., Silverberg S.J., et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999, 84(5):1562-1566.
17. Dempster D.W., Muller R., Zhou H., et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 2007, 41(1):19-24.
18. Silverberg S.J., Shane E., de la C.L., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989, 4(3):283-291.
19. Parisien M., Cosman F., Mellish R.W., et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 1995, 10(9):1393-1399.
20. Miller P.D., Bilezikian J.P. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N98-N102.
21. Wermers R.A., Khosla S., Atkinson E.J., et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006, 21(1):171-177.
22. Silverberg S.J. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin North Am 2000, 29(3):451-464.
23. Palmer M., Jakobsson S., Akerstrom G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Invest 1988, 18(1):39-46.
24. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94(2):335-339.
25. Silverberg S.J., Shane E., Jacobs T.P., et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
26. Rubin M.R., Bilezikian J.P., McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15-years. J Clin Endocrinol Metab 2008, 93(9):3462-3470.
27. Siilin H., Lundgren E., Mallmin H., et al. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg 2011, 35(6):1266-1272.
28. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312(7041):1254-1259.
29. Cummings S.R., Cawthon P.M., Ensrud K.E., et al. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006, 21(10):1550-1556.
30. Bilezikian J.P., Potts J.T., Fuleihan G.E., et al. Summary statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002, 17:N2-N11.
31. Bilezikian J.P. Bone strength in primary hyperparathyroidism. Osteoporos Int 2003, 14(Suppl 5):113-117.
32. Parfitt A.M. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17(10):1741-1743.
33. Khosla S., Melton L.J., Wermers R.A., et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999, 14(10):1700-1707.
34. Vestergaard P., Mollerup C.L., Frokjaer V.G., et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000, 321(7261):598-602.
35. Vignali E., Viccica G., Diacinti D., et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94(7):2306-2312.
36. Wilson R.J., Rao S., Ellis B., et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988, 109:959-962.
37. Vestergaard P., Mosekilde L. Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. J Intern Med 2004, 255(1):108-114.
38. Larsson K., Ljunghall S., Krusemo U.B., et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993, 234(6):585-593.
39. Parfitt A.M., Rao D.S., Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 1991, 6(Suppl 2):S97-S101.
40. Lewiecki E.M., Bilezikian J.P., Jankowski L.G., et al. Proceedings of the 2011 Santa Fe Bone symposium. J Clin Densitom 2012, 15(1):1-20.
41. Silverberg S.J., Lewiecki E.M., Mosekilde L., et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):351-365.
42. Maruani G., Hertig A., Paillard M., Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003, 88(10):4641-4648.
43. Bilezikian J.P., Silverberg S.J. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010, 54(2):106-109.
44. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis 1994, WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis, World Health Organization, Geneva, Switzerland.
45. Rejnmark L., Vestergaard P., Brot C., Mosekilde L. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 2011, 88(3):238-245.
46. Silva B.C., Costa A.G., Cusano N.E., et al. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest 2011, 34(10):801-810.